PA8549401A1 - Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido - Google Patents

Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Info

Publication number
PA8549401A1
PA8549401A1 PA20028549401A PA8549401A PA8549401A1 PA 8549401 A1 PA8549401 A1 PA 8549401A1 PA 20028549401 A PA20028549401 A PA 20028549401A PA 8549401 A PA8549401 A PA 8549401A PA 8549401 A1 PA8549401 A1 PA 8549401A1
Authority
PA
Panama
Prior art keywords
complex
osteoclastogenesis
inhibiting factor
polisacarido
includes inhibiting
Prior art date
Application number
PA20028549401A
Other languages
English (en)
Inventor
Yamamoto Shinichi
Okada Junichi
Kurihara Atsushi
Numazawa Taku
Kondo Junichi
Tsuda Eisuke
Mochizuki Shinichi
Nishi Hirotaka
Miyazaki Hideki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PA8549401A1 publication Critical patent/PA8549401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPLEJO QUE COMPRENDE POR LO MENOS UN FACTOR INHIBIDOR DE OSTEOCLASTOGENESIS (REFERIDO EN LO SUCESIVO COMO OCIF), O UN ANALOGO DEL MISMO O UNA VARIANTE DEL MISMO, Y POR LO MENOS UN POLISACARIDO O UN DERIVADO DEL MISMO, A UN METODO PARA PRODUCIR DICHO COMPLEJO, A UN MEDICAMENTO PARA TRATAR O PREVENIR ENFERMEDADES METABOLICAS OSEAS QUE COMPRENDE EL COMPLEJO COMO INGREDIENTE ACTIVO, Y AL USO DE DICHO COMPLEJO PARA TRATAR O PREVENIR ENFERMEDADES METABOLICAS OSEAS.
PA20028549401A 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido PA8549401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
PA8549401A1 true PA8549401A1 (es) 2003-07-28

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028549401A PA8549401A1 (es) 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Country Status (22)

Country Link
US (3) US20030045456A1 (es)
EP (1) EP1270015A3 (es)
KR (1) KR20030003124A (es)
CN (1) CN1442201A (es)
AR (1) AR034716A1 (es)
AU (1) AU783126B2 (es)
BR (1) BR0202439A (es)
CA (1) CA2392383A1 (es)
CO (1) CO5390084A1 (es)
CZ (1) CZ20022231A3 (es)
HK (1) HK1048762A1 (es)
HU (1) HUP0202119A2 (es)
IL (1) IL150448A0 (es)
MX (1) MXPA02006511A (es)
NO (1) NO20023144L (es)
PA (1) PA8549401A1 (es)
PE (1) PE20030254A1 (es)
PL (1) PL354799A1 (es)
RU (1) RU2232594C2 (es)
SG (1) SG98059A1 (es)
SK (1) SK9492002A3 (es)
ZA (1) ZA200205164B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
CN1183961C (zh) 1998-10-28 2005-01-12 三共株式会社 骨代谢异常症治疗剂
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
RS89204A (en) 2002-04-10 2006-12-15 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US31725A (en) * 1861-03-19 Improvement in cultivators
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US4207A (en) * 1845-09-27 lewis
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US139325A (en) * 1873-05-27 Improvement in carriage-springs
TW318142B (es) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CA2269114A1 (en) * 1997-09-24 1999-03-24 Snow Brand Milk Products Co., Ltd. Method for diagnosis of metabolic bone diseases
AU4061899A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Thienodipyridine derivatives, production and use thereof
CN1183961C (zh) * 1998-10-28 2005-01-12 三共株式会社 骨代谢异常症治疗剂
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
PA8568001A1 (es) * 2002-03-01 2003-11-12 Sankyo Co Composicion farmaceutica

Also Published As

Publication number Publication date
US20030045456A1 (en) 2003-03-06
PE20030254A1 (es) 2003-03-19
RU2232594C2 (ru) 2004-07-20
HU0202119D0 (es) 2002-08-28
US20060084595A1 (en) 2006-04-20
ZA200205164B (en) 2003-03-24
AR034716A1 (es) 2004-03-17
NO20023144D0 (no) 2002-06-28
AU5071902A (en) 2003-01-02
IL150448A0 (en) 2002-12-01
RU2002117385A (ru) 2004-01-27
MXPA02006511A (es) 2004-08-11
KR20030003124A (ko) 2003-01-09
PL354799A1 (en) 2002-12-30
EP1270015A2 (en) 2003-01-02
US20030139325A1 (en) 2003-07-24
AU783126B2 (en) 2005-09-29
CO5390084A1 (es) 2004-04-30
SG98059A1 (en) 2003-08-20
HK1048762A1 (zh) 2003-04-17
CA2392383A1 (en) 2002-12-29
HUP0202119A2 (hu) 2003-04-28
BR0202439A (pt) 2003-06-10
NO20023144L (no) 2002-12-30
CN1442201A (zh) 2003-09-17
EP1270015A3 (en) 2004-02-25
SK9492002A3 (en) 2003-02-04
CZ20022231A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP056138A (es) Dihidroquinazolinas sustituidas
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
GT199900203A (es) Composiciones de celecoxib.
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
EP1741430A4 (en) REMEDY FOR PSYCHO NEUROSIS DISEASES
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
HN2003000104A (es) Derivados de ciclopenteno
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis